Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$8.26M$8.26M−33.5% vs Q3 2019 Net Income-$16.55M-$16.55MN/M vs Q3 2019 EPS Diluted-$0.49-$0.49N/M vs Q3 2019 Operating Income-$13,781,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,351,000N/M Margins · derivedOperating margin-166.8%−78.2 pt vs Q3 2019
Net margin-200.4%−52.1 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 4, 2020 · 35 d after period end